Test Price
2,800 AED✅ Home Collection Available
NLRP1 Gene Corneal Intraepithelial Dyskeratosis and Ectodermal Dysplasia NGS Test in UAE | 2,800 AED
Executive Summary & Core Metrics
Comprehensive next-generation sequencing analysis of the NLRP1 gene detecting pathogenic variants linked to corneal intraepithelial dyskeratosis and ectodermal dysplasia with 99.9% diagnostic sensitivity.
- Diagnostic Accuracy: 99.9% Sensitivity | ISO 9001:2015 Accredited Laboratory.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily 8 AM – 11 PM).
- Post-Test Guidance: Complimentary telephonic result interpretation by a DHA-licensed Consultant Medical Genetics.
- Insurance Verification: Direct billing confirmation via WhatsApp +971 54 548 8731.
- Data Privacy: Compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
This targeted next-generation sequencing (NGS) assay interrogates the entire coding region and splice sites of the NLRP1 gene to identify single nucleotide variants, small insertions/deletions, and copy number variations associated with corneal intraepithelial dyskeratosis and ectodermal dysplasia. Results provide definitive molecular confirmation for ophthalmologists and clinical geneticists, enabling precise diagnosis, familial risk stratification, and tailored management planning. Testing is performed on an Illumina™ platform with a minimum mean depth of 100× coverage, ensuring robust variant calling and high-confidence reporting.
| Feature | NLRP1 NGS Test (Our Service) | Conventional Sanger Sequencing |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity; detects SNVs, indels, and CNVs across full coding region | ~95% sensitivity; limited to targeted exons, misses large rearrangements |
| Methodology | Next Generation Sequencing on Illumina™ platform, 100× mean depth | Sanger sequencing of individually amplified exons |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Sample Collection | VIP Mobile Phlebotomy home visit (8 AM – 11 PM) with cold-chain transport | Typically clinic-based draw only |
| Post-Test Support | Free telephonic clinical interpretation by DHA-licensed Consultant Medical Genetics | Report only, no interpretation service |
Physician Insight & Safety Protocols
“As a DHA-licensed Consultant Medical Genetics specializing in hereditary ocular and cutaneous disorders, I emphasize that this NGS assay provides high-confidence molecular evidence but must always be interpreted alongside comprehensive clinical, ophthalmological, and dermatological findings. Pathogenic NLRP1 variants require correlation with family history and phenotypic presentation. Patients should continue all prescribed therapies and consult their treating physician before any management changes.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Important Safety Advisory
Medication Continuation & Clinical Oversight
Do not discontinue or alter any prescribed ophthalmic, dermatologic, or systemic medication without direct consultation with your managing physician. This genetic test is a diagnostic adjunct and does not replace routine clinical monitoring, ongoing therapy, or specialist follow-up for corneal or skin conditions.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria: Individuals with known coagulation disorders requiring specialized venipuncture precautions, active febrile illness, severe anemia (hemoglobin <7 g/dL), or inability to provide informed consent are not eligible for mobile phlebotomy and must arrange sample collection at a clinical facility.
Emergency Red Flags: If you experience sudden vision loss, severe ocular pain, rapid corneal opacification, or generalized blistering skin eruptions, seek immediate evaluation at the nearest emergency department. This test does not address acute presentations.
Patient FAQ & Clinical Guidance
1. What clinical conditions does the NLRP1 gene test detect?
This targeted NGS panel identifies disease-causing variants in the NLRP1 gene associated with corneal intraepithelial dyskeratosis and ectodermal dysplasia. It provides a definitive molecular diagnosis for individuals presenting with corneal opacification, vascularization, or characteristic skin and adnexal findings, and enables familial risk assessment for at-risk relatives.
2. How is the sample collected for this genetic test?
A certified phlebotomist performs a minimally invasive peripheral whole-blood draw during a scheduled VIP home visit between 8 AM and 11 PM. The specimen is transported under temperature-controlled cold-chain conditions to our ISO-accredited laboratory. Alternatively, extracted DNA or FTA card samples may be accepted upon prior coordination.
3. Can my UAE health insurance cover the cost of this test?
Our billing team verifies coverage directly with your health insurer and obtains pre-approval on your behalf. Share your policy details via WhatsApp at +971 54 548 8731 for a seamless, fully transparent billing experience with no unexpected out-of-pocket costs.
4. How long does it take to get results?
The standard turnaround time is 3–4 weeks from sample receipt in the laboratory. This timeline accommodates library preparation, sequencing, bioinformatic analysis, variant classification per ACMG guidelines, and physician-reviewed reporting.
5. Will I receive support to understand my results?
Yes. Every report includes a complimentary telephonic consultation with our DHA-licensed Consultant Medical Genetics, who explains the clinical significance of findings, discusses inheritance patterns, and coordinates with your referring specialist for integrated care planning.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in full compliance with UAE federal data protection and health information governance frameworks. All genetic data generated through this test is processed, stored, and transmitted under strict confidentiality controls aligned with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — governing the lawful collection, processing, and transfer of personal health data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — regulating digital health records, telemedicine, and electronic data exchange.
- Federal Decree-Law No. 4 of 2016 on Medical Liability — establishing standards for clinical testing safety, patient consent, and professional accountability.
Our laboratory is DHA-licensed (Facility No. 1143) and adheres to international quality standards including ISO 9001:2015 and CAP/CLIA-equivalent protocols. Patient genetic information is never shared with third parties without explicit written consent except as required by UAE law.
Clinical & Logistical Metadata
| Test Name | NLRP1 Gene Corneal Intraepithelial Dyskeratosis and Ectodermal Dysplasia NGS Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (also accepts extracted DNA / FTA card) |
| Methodology Used | Next Generation Sequencing (NGS) on Illumina™ Platform, 100× Mean Depth |
| ICD-10-CM Code | Q82.4, H18.89 |
| LOINC Code | 94222-8 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians